Ray Tracing-Guided Lasik Surgery: 1-Year Clinical Observation

 This study systematically evaluated the clinical efficacy of ray tracing-guided LASIK surgery in correcting refractive errors through 1-year follow-up, analyzing its safety, efficacy, predictability, and long-term stability.

Retrospective Study

Patients who underwent ray tracing-guided LASIK at our hospital from October 2023 to October 2024 were enrolled. All patients underwent routine preoperative examinations, with biometric parameters detected and measured using the InnovEyes Sightmap diagnostic device. Ablation profiles were calculated using the InnovEyes algorithm. Postoperative refractive outcomes were assessed at 1 year.

A total of 67 patients (134 eyes) were enrolled. Postoperative UDVA achieved 20/20, 20/16, and 20/12.5 in 100%, 81.34%, and 34.32% of patients, respectively. All patients attained preoperative CDVA, with 78% surpassing preoperative levels. CDVA improved by 1 line in 48% and 2 lines in 30%, with no patient losing vision. No over/under-correction occurred. SEQ was within ±1.00D in 100% and ±0.5D in 90%. Astigmatism was within ±1.00D in 98% and ±0.5D in 88%, with 87% having error angles within ±15°. SEQ stabilized by 3 months (+0.38 to +0.15), changing only 5% from 3 months to 1 year (+0.15 to -0.02). Total HOA at 1 year showed no significant difference from baseline (P>0.05).

Ray tracing-guided LASIK surgery is safe and effective, with significant visual improvement and excellent predictability. Refractive stability was achieved by 3 months postoperatively, confirmed by good long-term stability at 1-year follow-up. Astigmatism correction demonstrated high precision with ideal error control on vector analysis, making it suitable for patients requiring high-precision refractive correction.